Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | President | September 09, 2020 | September 11, 2020 |
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 02, 2021 | June 04, 2021 |
| BCLS Acquisition Corp.BLSA · Entity 145747 | Director | October 22, 2020 | October 22, 2020 |
| CITY THERAPEUTICS, INC.CTY · Entity 184066 | Director | October 15, 2026 | October 16, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | June 22, 2026 | June 23, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 09, 2020 · Filed September 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,412 |
Reported balance
After 2020-07-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-07-16 · Gift · Acquired 3,176 · Balance 65,412 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 114,873 |
Reported balance
After 2020-09-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-09-09 · Exercise / conversion · Acquired 44,530 · Balance 114,873 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 100,798 |
Reported balance
After 2020-09-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2020-09-09 · Sale · Disposed 14,075 · Balance 100,798 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F3: Sale prices ranged from $122.00 to $123.00. |
| Common StockSEC Table I · non-derivative | Direct | 73,689 |
Reported balance
After 2020-09-09 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2020-09-09 · Sale · Disposed 27,109 · Balance 73,689 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4: Sale prices ranged from $123.01 to $124.00. |
| Common StockSEC Table I · non-derivative | Direct | 70,343 |
Reported balance
After 2020-09-09 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2020-09-09 · Sale · Disposed 3,346 · Balance 70,343 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F5: Sale prices ranged from $124.03 to $124.87. |
| Common StockSEC Table I · non-derivative | Indirectby Dependent | 155 |
Reported balance
After 2020-07-16 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-07-16 · Gift · Acquired 155 · Balance 155 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,331 |
Reported balance
After 2020-07-16 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-07-16 · Gift · Disposed 155 · Balance 3,331 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,176 |
Reported balance
After 2020-07-16 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2020-07-16 · Gift · Disposed 155 · Balance 3,176 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 0 |
Reported balance
After 2020-07-16 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2020-07-16 · Gift · Disposed 3,176 · Balance 0 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2020-12-08 | Direct | 0 |
Reported balance
After 2020-09-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-09-09 · Exercise / conversion · Disposed 44,530 · Balance 0 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 3,003 |
Reported balance
Holding disclosure · report date 2020-09-09 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 3,003 F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person.
F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020.
F3: Sale prices ranged from $122.00 to $123.00.
F4: Sale prices ranged from $123.01 to $124.00.
F5: Sale prices ranged from $124.03 to $124.87.
F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Acorda Therapeutics, Inc.
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2031-06-02 | Direct | 10,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021.
BCLS Acquisition Corp.
Report date October 22, 2020 · Filed October 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
CITY THERAPEUTICS, INC.
Report date October 15, 2026 · Filed October 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2034-09-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying this option vest in 48 equal monthly installments following September 29, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in 48 equal monthly installments following September 29, 2024, subject to the Reporting Person's continued service on each such vesting date.
Dyne Therapeutics, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.87 · Expires 2036-06-21 | Direct | 57,463 |
Reported balance
After 2026-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 57,463 · Balance 57,463 F1: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,415 |
Reported balance
After 2026-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 16,415 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-07-31 · Other · Disposed 46,940 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-07-31 · Disposition to issuer · Disposed 53,229 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2035-01-16 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-31 · Disposition to issuer · Disposed 174,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2017 Filed Oct 4, 2017 23:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 85,316 | $125.00 | $10,664,500.00 |
DisclosureSEC source: 0001553878-17-000054 · primary_doc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,428 F1 · kind: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 85,316 | $21.35 | $1,821,496.60 |
DisclosureSEC source: 0001553878-17-000054 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,359 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 8 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,641 Underlying: Common Stock · 5,359 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,485 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 7 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,915 Underlying: Common Stock · 6,485 shares Expires 2021-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,359 | $18.66 | $99,998.94 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,485 | $7.10 | $46,043.50 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 76,815 | $0.00 Strike: $31.39 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 9 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,815 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. F1 · derivative.expiration_date: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2013 (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2023-12-17 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by the compensation committee of the Company. Effective September 20, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option was vested as to one-third of the shares. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 76,815 | $100.00 | $7,681,500.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,584 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 76,815 | $31.39 | $2,411,222.85 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $18.21 | $0.00 |
DisclosureSEC source: 0001209191-17-047299 · doc4.xml · derivative · entry 3 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F3 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 6/5/2008. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 10,000 | $21.57 | $215,697.00 |
DisclosureSEC source: 0001209191-17-047299 · doc4.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $21.30 to $21.95 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 10,000 | $18.21 | $182,100.00 |
DisclosureSEC source: 0001209191-17-047299 · doc4.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:34 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2014 (right to buy) · Derivative | 15,875 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000042 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 15,875 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:47 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-17-040558 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 09:08 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-17-036997 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on May 31, 2017, with the first quarterly installment vesting on August 31, 2017. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 723 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001209191-17-009970 · doc4.xml · derivative · entry 3 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 723 shares Expires 2017-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F2 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 2/14/2008. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 723 | $22.65 | $16,375.95 |
DisclosureSEC source: 0001209191-17-009970 · doc4.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 723 | $22.13 | $15,999.99 |
DisclosureSEC source: 0001209191-17-009970 · doc4.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:12 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 3,017 | $0.00 Strike: $15.91 | $0.00 |
DisclosureSEC source: 0001209191-17-001997 · doc4.xml · derivative · entry 3 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,017 shares Expires 2017-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F3 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 1/09/2008. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:12 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,017 | $19.26 | $58,112.85 |
DisclosureSEC source: 0001209191-17-001997 · doc4.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $18.95 to $19.70 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:12 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 3,017 | $15.91 | $48,000.47 |
DisclosureSEC source: 0001209191-17-001997 · doc4.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:19 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-16-000106 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 F1 · shares: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,605 | $0.00 Strike: $22.75 | $0.00 |
DisclosureSEC source: 0001553878-16-000061 · primary_doc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,605 shares Expires 2016-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2016. The 31,825 options exercised and sold and the 23,780 options exercised and held by the reporting person were due to expire on December 14, 2016. F6 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. F1 · derivative.expiration_date: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2016. The 31,825 options exercised and sold and the 23,780 options exercised and held by the reporting person were due to expire on December 14, 2016. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 500 | $44.07 | $22,036.00 |
DisclosureSEC source: 0001553878-16-000061 · primary_doc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,584 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2016. The 31,825 options exercised and sold and the 23,780 options exercised and held by the reporting person were due to expire on December 14, 2016. F4 · price: Sale prices ranged from $44.00 to $44.13. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 16,976 | $43.28 | $734,746.74 |
DisclosureSEC source: 0001553878-16-000061 · primary_doc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,084 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2016. The 31,825 options exercised and sold and the 23,780 options exercised and held by the reporting person were due to expire on December 14, 2016. F3 · price: Sale prices ranged from $43.00 to $43.92. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14,349 | $42.61 | $611,344.88 |
DisclosureSEC source: 0001553878-16-000061 · primary_doc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,060 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2016. The 31,825 options exercised and sold and the 23,780 options exercised and held by the reporting person were due to expire on December 14, 2016. F2 · price: Sale prices ranged from $42.00 to $42.99. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 55,605 | $22.75 | $1,265,013.75 |
DisclosureSEC source: 0001553878-16-000061 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2016. The 31,825 options exercised and sold and the 23,780 options exercised and held by the reporting person were due to expire on December 14, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.